Loading...
Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
The therapeutic approach to Chronic Myeloid Leukemia (CML) has changed since the advent of the tyrosine kinase inhibitor (TKI) imatinib, which was then followed by the second generation TKIs dasatinib, nilotinib, and, finally, by ponatinib, a third-generation drug. At present, these therapeutic opti...
Na minha lista:
| Udgivet i: | Int J Mol Sci |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7352889/ https://ncbi.nlm.nih.gov/pubmed/32586039 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21124469 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|